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Extended-spectrum 𝛽-lactamases (ESBLs) prevalence was studied in the north of Portugal, among 193 clinical isolates belonging
to citizens in a district in the boundaries between this country and Spain from a total of 7529 clinical strains. In the present study
we recovered some members of Enterobacteriaceae family, producing ESBL enzymes, including Escherichia coli (67.9%), Klebsiella
pneumoniae (30.6%), Klebsiella oxytoca (0.5%), Enterobacter aerogenes (0.5%), and Citrobacter freundii (0.5%). 𝛽-lactamases genes
blaTEM, blaSHV, and blaCTX-M were screened by polymerase chain reaction (PCR) and sequencing approaches. TEM enzymes
were among the most prevalent types (40.9%) followed by CTX-M (37.3%) and SHV (23.3%). Among our sample of 193 ESBL-
producing strains 99.0% were resistant to the fourth-generation cephalosporin cefepime. Of the 193 isolates 81.3% presented
transferable plasmids harboring 𝑏𝑙𝑎ESBL genes. Clonal studies were performed by PCR for the enterobacterial repetitive intragenic
consensus (ERIC) sequences. This study reports a high diversity of genetic patterns. Ten clusters were found for E. coli isolates and
five clusters for K. pneumoniae strains by means of ERIC analysis. In conclusion, in this country, the most prevalent type is still the
TEM-type, but CTX-M is growing rapidly.
1. Introduction
Extended-spectrum 𝛽-lactamases (ESBLs) are enzymes that
confer resistance to aztreonam, cefotaxime, ceftazidime,
and related oxyimino-𝛽-lactams as well as to other peni-
cillins and cephalosporins but are inhibited by clavu-
lanic acid [1]. ESBL-producing Enterobacteriaceae were first
reported in Europe in the 1980s and have since become
a worldwide problem [2]. This has resulted in increased
morbidity, mortality, and cost in treating the infections
they cause [3]. The first ESBL were mutants of the TEM
and SHV plasmid-mediated penicillinases with one or
more amino acid substitutions. The mutations confer resis-
tance to all oxyimino-cephalosporins but not 𝛼-methoxy-
cephalosporins (cephamycins) or carbapenems by causing
enlargement of ESBL active site, which allowed the deflection
of the oxyimino group diminishing the attack efficiency
on the 𝛽-lactam ring [4]. TEM and SHV present to date
over 200 members known (http://www.lahey.org/studies).
Another ESBL group includes the CTX-M enzymes that are
organized in five major CTX-M groups: 1, 2, 8, 9, and 25 [5].
The CTX-M comprises a rapidly growing family distributed
both over wide geographic areas and among a wide range
of bacteria of clinical significance and is becoming more
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prevalent than its ancestors TEM and SHV [6]. Several
studies have been reported in Iberian Peninsula describing
the genetic and clinical environments of ESBL occurrence
[7–12]. Here we report the molecular and antimicrobial
susceptibility profile of the ESBL-producing clinical isolates,
found in the Portuguese occidental coast in the boundaries
between the two countries, Portugal and Spain. For this
task we used methods of molecular typing which have been
developed for the identification of the 𝛽-lactamases bla genes
from both hospitalized and nonhospitalized patients for a
period of two years.
2. Materials and Methods
2.1. Bacterial Strains, Identification, and Susceptibility. A total
of 7529 clinical strains were included in the study. All isolates
were gently provided from Clinical Pathology Laboratories
and belong to patients samples recovered from September
2008 to August 2010 in the northern occidental coast of the
Portuguese territory known asMinho (Portugal).This region
comprises several populations of the north of Portugal and
some at the boundaries with Galicia (Spain). Microbial iden-
tification and preliminary antimicrobial susceptibility were
determined according to Clinical and Laboratory Standards
Institute guidelines [13]. ESBL production was confirmed by
the ellipsoid method, using two 𝐸-test Strips (AB Biodisk,
Sweden), namely, TZ/TZL (ceftazidime and clavulanic) and
CT/CTL (cefotaxime and clavulanic).
2.2. Conjugation Experiments. Transmissibility of resistance
was studied by matting clinical isolates with the E. coli
J53 AziR (azide resistant) on Trypticase soy broth (TSB)
according to a method described previously [14].
2.3. Analytical Isoelectric Focusing (IEF). Crude prepara-
tions of 𝛽-lactamases from clinical strains transconjugants
were obtained by sonication in phosphate buffer, pH 7.0,
as described previously [15]. Briefly crude extracts were
concentrated and a nitrocefin solution was added. The color
change from yellow to red indicates a positive 𝛽-lactamase
production. The sample then was run on an IEF minigel,
pH 3–10, for 30 minutes. 𝛽-lactamases isoelectric point (pI)
was determined by pouring molten 3% agarose containing
nitrocefin over the gel and comparing the bands to standards
run on the same gel. The 𝛽-lactamase standards used were
TEM-1, pI 5.4, SHV-5, pI 8.2, and CTX-M-14, pI 8.1.
2.4. Genetic Molecular Characterization of bla Genes and
Typing. A single colony of each transconjugant was left
to grow for 16 h on MacConkey agar and was placed in
200𝜇L sterile water in a 1.5mL microtube. Each tube was
heated in a microwave oven at 600–700W for 2min to burst
the cells and release their DNA. PCR was performed as
described previously [15]. The recovered bands from agarose
gels were cloned for further sequencing. The nucleotide
sequences of both ends of the insert were determined with
M13 sequencing primers specific for the cloning vector [16].
ERIC profiles were analyzed with software FPQuest version
4.5, Fingerprinting II (Bio-Rad Laboratories, CA, USA).
3. Results
The prevalence of ESBL-producing strains in the north
Portuguese territory was 2.6% (𝑛 = 193). The most frequent
ESBL-producing organism was E. coli (67.9%, 𝑛 = 131),
followed byK. pneumoniae (30.6%, 𝑛 = 59),K. oxytoca (0.5%,
𝑛 = 1), E. aerogenes (0.5%, 𝑛 = 1), and C. freundii (0.5%, 𝑛 =
1) as shown in Table 1. ESBL-producing strains were isolated
from urine (𝑛 = 127), sputum (𝑛 = 42), bronchoalveolar
lavage (𝑛 = 14), bloodstream (𝑛 = 7), and ascitic fluid (𝑛 = 3).
PCR studies allowed detecting several ESBL enzyme
types. TEM enzymes were the most frequent ESBL types
(40.9%), followed by CTX-M (37.3%) and finally SHV
(23.3%). Sequencing confirmedESBL and allowed identifying
the enzyme variant. TEM-52 and TEM-24 were the most
frequent TEM types, 20.2% (𝑛 = 39) and 12.9% (𝑛 = 25),
respectively. Members of the TEM-10 (𝑛 = 8) and TEM-
116 (𝑛 = 4) were also detected. Within CTX-M family, the
CTX-M-9 group is more prevalent than the CTX-M-1 group
(58.3% against 41.6%). CTX-M-9 group was represented by
CTX-M-9 (𝑛 = 26, 36.1%) and CTX-M-14 (𝑛 = 16, 22.2%).
In the CTX-M-1 group, CTX-M-15 was most frequent type
(𝑛 = 24, 33.3%), followed by CTX-M-1 (𝑛 = 4, 5.5%), CTX-
M-3 (𝑛 = 1, 1.3%), and CTX-M-32 (𝑛 = 1, 1.3%). The
SHV enzymes occurred only in 23.3% of all ESBL-producing
organisms. Within this type, the most frequent was the SHV-
12 variant (𝑛 = 24, 53.3%), followed by SHV-5 (𝑛 = 17, 37.8%)
and finally SHV-2 (𝑛 = 4, 8.8%). Some isolates coproduced
more than oneESBL type: TEM-52/CTX-M-14 (𝑛 = 1), TEM-
116/CTX-M-14 (𝑛 = 1), and TEM-116/CTX-M-15 (𝑛 = 1).
Regarding antibiotic susceptibility the present study
shows that ESBL-producing strains were extremely resistant
to cefepime (99.0%) and susceptible to carbapenems (100%).
In what concerns to interspecific genetic similarity, it was
observed a high genetic diversity. It was possible to define
10 clusters (A to J) for E. coli based on Pearson’s correlation
coefficient in PCR-ERIC based profile. For K. pneumoniae 5
different clusters (K to O) were defined for the PCR-ERIC
(data presented as Supplementry Material available online
at http://dx.doi.org/10.1155/2014/782897).
4. Discussion
As reported in previous Portuguese [9–12, 14, 15, 17–19],
Spanish [8, 20, 21], and other European [6] studies E. coli
and K. pneumonia are the species where ESBL is the most
frequently identified. In this study E. coli was the most
frequent (𝑛 = 131) organism expressing ESBL phenotypes,
more than twofold of the K. pneumonia (𝑛 = 59), the second
most frequent.
Regarding the high diversity ESBL types obtained in our
study, we find it interesting to comparewith neighbor regions,
such as Douro Litoral located at south of Minho, Tra´s-os-
Montes e Alto Douro, eastern, and the Spanish province of
Galiza, located at north of Minho (Figure 1).
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Table 1: Characterization of ESBL-producing strains.
ESBL IEF (pI) Microorganism(number of isolates)
Conjugation
(% positive)
Resistance phenotype (% nonsusceptible: I + R)
ERIC types patterns∗𝛽-Lactams Non-𝛽-lactams
CEP FOX CARB CIP GEN SXT
TEM-4 5.9 E. coli (2)K. pneumoniae (1)
100
100
100
100
50
0
0
0
100
100
50
100
100
0
A
L
TEM-10 6.0 E. coli (8) 87.5 100 25 0 87.5 0 75 B, D, H
TEM-24 6.5
E. coli (12)
K. pneumoniae (11)
K. oxytoca (1)
E. aerogenes (1)
83.3
81.8
100
100
100
100
100
100
50
20
100
0
0
0
0
0
75
72.7
100
0
8.3
50
0
100
8.3
63.6
100
100
C, G, H, I
K, L, O
n.a.
n.a.
TEM-52 6.0 E. coli (27)K. pneumoniae (12)
81.4
100
100
100
36.4
8.4
0
0
84.6
91.6
53.8
83.3
42.3
33.3
A, B, E, F, J
N, O
TEM-116 5.4 E. coli (𝑛 = 4) 100 100 50 0 75 75 0 F
SHV-2 7.6 K. pneumoniae (3)E. coli (1)
100
100
33.3
0
33.3
0
0
0
66.7
100
66.7
100
100
100
L
A
SHV-5 8.2 K. pneumoniae (11)E. coli (6)
72.7
83.3
100
100
27.3
66.7
0
0
63.6
100
72.7
100
27.3
0 L, N
SHV-12 8.2 K. pneumoniae (18)E. coli (6)
83.3
100
100
100
27.7
33.3
0
0
61.1
100
94.4
100
77.8
66.7
K, M, N, O
C, D, E
CTX-M-1 6.3 E. coli (1) 100 100 25 0 100 100 0 E
CTX-M-3 8.4 C. freundii (1) 0 100 0 0 0 100 0 n.a.
CTX-M-9 8.1 E. coli (26) 92.3 100 26.9 0 96.2 84.6 3.8 A, C, D, G, I, J
CTX-M-14 8.1 E. coli (16) 68.8 100 12.5 0 100 75 0 D, F, H, J
CTX-M-15 8.6 E. coli (21)K. pneumoniae (3)
85.7
100
100
100
38.1
100
0
0
100
100
90.5
100
14.3
100
A, C, E, I, J
N
CTX-M-32 9.0 E. coli (1) 100 100 0 0 100 100 0 D
ESBL: extended-spectrum 𝛽-lactamase; IEF: isoelectric focusing; pI: isoelectric point; I: intermediate; R: resistant; n.a.: not applicable. Antimicrobials: CEP:
cefepime; FOX: cefoxitin; CARB: carbapenems (imipenem and meropenem); CIP: ciprofloxacin; Gen: gentamicin; SXT: combination of trimethoprim and
sulfamethoxazole.
∗Supplementary Material.
From this evaluation and regarding ESBL-TEM types data
suggests that TEM-10, TEM-20, TEM-26, and TEM-116 from
E. coli and TEM-4 from K. pneumoniae were present not
only in the region analyzed in the present study (Minho)
but also in other locations of Iberian Peninsula. E. coli
strains producing SHV-2 and SHV-5 were also found not
only in Minho, Portugal, but also in other regions of Iberian
Peninsula [8].
Regarding CTX-M types, it seems that CTX-M-14 is
widespread within the northwestern Iberian Peninsula. K.
pneumoniae harboring a CTX-M-15 was described for the
first time in Portugal in 2005 [22] in Lisbon area, but
it is also found in the north of Portugal in this study
and Douro [9]. The high frequency of CTX-M-15 enzymes
found in the present work is in agreement with the major
studies worldwide that report the emergence of CTX-M-15
producing E. coli as new threat [21].
Cefepime presents, in this study, a surprisingly low
activity against ESBL-producing microorganisms. In our
sample only twoK. pneumoniaeharboring SHV-2ESBLswere
susceptible to cefepime. All the other clinical isolates 99.0%
(𝑛 = 191) expressing the ESBL phenotype were resistant
to cefepime. It seems interesting that a recent study showed
that cefepimewas successfully administrated to three patients
(two females and one male) with ages between 47 and 87
years old carrying a gram-negative ESBL positive strain [27].
Nevertheless other studies worldwide start to describe the
emergence of high resistance among ESBL gram-negative
producers [12, 28, 29].
Regarding the age of the patients, 82% of those infected
with an ESBL-producing pathogen are more than 60 years
old. This finding is in accordance with a recent work
that states that age over 65 years old is a risk factor for
𝛽-lactamase-mediated resistance to oxyimino-𝛽-lactams in
patients infected with enterobacteria [30].
Finally, considering the genetic relatedness of 191 iso-
lates studied, by ERIC analysis, it is possible to propose
10 clusters for E. coli and 5 clusters for K. pneumoniae.
This finding suggests a pronounced genetic diversity among
ESBL-producing clones. Similar studies in southern Portugal
considering simply ESBL-producing K. pneumoniae isolates
have also demonstrated this extraordinary genetic diversity
[31].
Furthermore, several studies suggest that in Portugal the
presence of ESBL genes not only in clinical context but also in
the environment, foodstuff, food-producing animals, selvage
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Figure 1: Occurrence of ESBL-TEM, ESBL-SHV, and ESBL-CTX-M types in the north of Portugal. The present study, territory, Minho,
is represented at the map in yellow. Other regions either from Portugal vs Spain are represented in different shades of green and gray
or, respectively. Data was collected from the present study (yellow) and from several studies in these two countries [8–12, 14, 15, 17–26].
[ECO:Escherichia coli; ENT:Enterobacter spp.; KP:Klebsiella pneumoniae; K:Klebsiella spp.; SAL:Salmonella enterica].
animals, waters (wasters and for human consumption). In
general these studies show an increasing concern for these
matters, an increasing of antibiotic resistance genes among
other environments not associated with healthcare, and
uncontrolled use of antibiotics with prolonged exposure
often resulting in bacterial resistance [32–38]. Interestingly,
regarding this matter, members of the team have identi-
fied three new TEM variants, within water and foodborne
enterobacterial pathogens (TEM-179, TEM-180, and recently
TEM-201) but not within the clinic isolates [37].
5. Conclusion
In summary, we reported the high biochemical and genetic
diversity of ESBL enzymes occurring in Portugal. In this
country, the most prevalent type is still the TEM type, but
CTX-M is growing rapidly. Similarly high genetic diversity
among ESBL-encoding strains is also observed by means of
ERIC that allowed detecting distinct phylogenetic relation-
ships between the different Enterobacteriaceae isolates.
The present study also provides strong evidence that
resistance to fourth-generation cephalosporins is a matter
of major concern in our country. The emergence of ESBL
producers resistant to cefepime in Portugal may indicate the
uncontrolled use of cephalosporins and that is an issue that
we strongly believe is urgent to investigate.
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